drugset / Trial / NCT03581240
An Intermediate Expanded Use Trial of DFMO
Summary
To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | 500 mg/m2 | Oral |
| Subject | Eflornithine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Eflornithine | Small molecule | 2500 mg/m2 | Oral |